SiteOne Therapeutics Inc, a private biopharmaceutical company, announced on Tuesday that it has named John Mulcahy, PhD as its new chief executive officer.

Dr Mulcahy is one of the company's scientific co-founders and has headed the strategic and technical drug discovery efforts at the company since its founding. Mulcahy is to replace Stan Abel.

Dr Mulcahy has earlier served as the vice president of research at SiteOne. He has served as principal investigator on multiple grants from the US Department of Defense and National Institutes of Health.